

Press release

New product for diabetes detection, Diab-spot, introduced in Madrid.

Groningen, the Netherlands – April 19, 2011

At the 4th International Congress on Prediabetes and the Metabolic Syndrome in Madrid dr. A.J. Smit presented the results of a clinical trial with Diab-spot, a new noninvasive ptool for diabetes detection.

Diab-spot uses the measurement of Advanced Glycation Endproducts (AGEs) and a small number of characteristics to calculate a diabetes risk score. This noninvasive Diab-spot screening measurement takes no longer than one minute. The detection of (pre-)diabetes patients by Diab-spot is superior to FPG and HbA1c. Diab-spot is the second product of DiagnOptics. This Dutch medical technology company was the first to introduce a technology to noninvasively measure the tissue accumulation of tissue AGEs with the AGE Reader.

In order to reduce diabetes associated complications and mortality there is a great need for screening and monitoring methods to assess the risk of diabetes and diabetic complications. If (pre-)diabetes is detected early, with only lifestyle, or with pharmaceutical interventions the development of diabetes and its complications can be postponed or even prevented.

“The ease of use in any point of care setting, its non invasive character and the immediately available result qualify Diab-spot as an excellent tool for the detection of (pre-)diabetes” says DiagnOptics’ managing director Bart van den Berg.

About DiagnOptics

DiagnOptics is the pioneer and inventor of cutting edge diagnostic devices that can non-invasively diagnose and assess the risk of diabetes and its complications. Its technological advance in detecting fluorescence of Advanced Glycation Endproducts (AGEs) has led to the invention of the AGE Reader - a state of art diagnostic device which can determine the tissue accumulation of AGEs in 30 seconds. Since the CE certification on the AGE Reader in 2006, DiagnOptics has been marketing this medical device to hundreds of clinics around the world. Currently the company is working on obtaining additional regulatory approvals in other regions and is engaged in new product development activities. The head office of DiagnOptics Technologies BV is in Groningen, the Netherlands. [Read more.](#)

Contact:

Bart van den Berg
Managing Director

DiagnOptics Technologies B.V.
L.J. Zielstraweg 1, Meditech Center
9713 GX Groningen
the Netherlands
www.diagnoptics.com



tel: +31 (0)50 5890612

direct tel: +31 (0)6 54228480

e-mail: b.vandenberg@diagnoptics.com

